Elevation of Vascular Endothelial Growth Factor-A Serum Levels Following Acute Myocardial Infarction. Evidence for its Origin and Functional Significance
A. Kranz, C. Rau, M. Kochs and J. Waltenberger. Elevation of Vascular Endothelial Growth Factor-A Serum Levels Following Acute Myocardial Infarction. Evidence for its Origin and Functional Significance. Journal of Molecular and Cellular Cardiology (2000) 32, 65–72. Following the onset of acute myoca...
Gespeichert in:
Veröffentlicht in: | Journal of molecular and cellular cardiology 2000-01, Vol.32 (1), p.65-72 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A. Kranz, C. Rau, M. Kochs and J. Waltenberger. Elevation of Vascular Endothelial Growth Factor-A Serum Levels Following Acute Myocardial Infarction. Evidence for its Origin and Functional Significance. Journal of Molecular and Cellular Cardiology (2000) 32, 65–72. Following the onset of acute myocardial infarction (AMI), a number of serum parameters show well-defined changes reflecting myocardial injury. During the consecutive repair phase, compensatory processes are initiated including the formation of a collateral circulation on the basis of angiogenesis and arteriogenesis. An important angiogenic factor is vascular endothelial growth factor-A (VEGF-A), shown to be upregulated in the ischemic myocardium. It is unclear, however, whether acute myocardial ischemia leads to a detectable elevation of VEGF-A serum concentrations. With the use of an immunoradiometric assay, we measured the levels of VEGF-A in the serum of patients after AMI at defined time intervals, of patients with unstable angina pectoris (UAP) and of healthy individuals. In addition, in a small group of patients with subacute myocardial infarction VEGF-A concentrations were measured in coronary sinus blood. The data are given as median followed by the 25th and 75th percentiles. In the group with AMI serum VEGF-A measured 105 [78; 176] pg/ml on day 1 and 114 pg/ml [72; 163] pg/ml on day 3 after onset of AMI. Serum levels of VEGF-A significantly increased on day 7 after AMI to 189 [119; 373] pg/ml (P=0.0103) and on day 10 to 255 [162; 371] pg/ml (P=0.0007). The VEGF-A serum level in healthy controls and in patients with UAP measured 98 [75; 137] pg/ml and 116 [57; 140] pg/ml, respectively. Serum at day 10 after AMI contained VEGF-A at a biologically relevant concentration capable of stimulating proliferation of endothelial cells. Surprisingly, VEGF-A serum levels were similar in samples taken from the coronary sinus with 61 [43; 83] pg/ml. Therefore the main source for VEGF-A in the blood stream is not the infarcted myocardium. However, the number of platelets, a rich source of VEGF-A, is significantly increased after myocardial infarction, i.e. 284 [252; 363]×109/litre v 220 [177; 250]×109/litre. In conclusion, the time course of VEGF-A elevation following AMI strongly suggests that VEGF-A plays a role as an endogenous activator of coronary collateral formation in the human heart. The most likely source of the elevated VEGF-A are platelets, rather than the infarcted myocardium. |
---|---|
ISSN: | 0022-2828 1095-8584 |
DOI: | 10.1006/jmcc.1999.1062 |